Why Equi Sciences

The industry outlook for clinical trials in the United States is very promising, with a projected Compound Annual Growth Rate (CAGR) of 5% from 2022 to 2030. However, despite the substantial volume of scheduled and ongoing trials nationwide, minority representation in these studies remains disproportionately low, accounting for only 4 to 5 percent of participants. This disparity presents a significant opportunity for EQUI Sciences, which is dedicated to educating and recruiting minority groups for participation in clinical research, thereby addressing the critical need for greater inclusivity and diversity in medical studies.